About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.Janssen.com/korea. Janssen Korea is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
RYBREVANT® (amivantamab) is approved for the treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. RYBREVANT® is the first fully-human, bispecific antibody approved for the treatment of NSCLC that targets EGFR exon 20 insertion mutations. RYBREVANT® is a bispecific antibody directed against EGFR and MET receptors. It disrupts EGFR and MET signaling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumor growth and progression. The initial approval for EGFR exon 20 mutations is supported by data from the monotherapy arm of the ongoing Phase 1 CHYRSALIS trial, a multi-center, open-label, multi-cohort study (NCT02609776).